There is no benefit to LNK, particularly at this low smashed SP. Mere distraction from the board'ss poor performance from first take-over north of $5.5 highs all the way down.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%